Investigating customised positive airway pressure therapy masks versus usual care in the treatment of patients with sleep-disordered breathing

Submission date	Recruitment status	[X] Prospectively registered			
07/12/2022	No longer recruiting	[X] Protocol			
Registration date	Overall study status	Statistical analysis plan			
10/01/2023	Ongoing Condition category	Results			
Last Edited		Individual participant data			
08/05/2025	Respiratory	[X] Record updated in last year			

Plain English summary of protocol

Background and study aims

In the UK alone, there are 1.6 million people who have problems with their breathing during sleep. The best treatment is a breathing machine, which is attached via a tube with a tight-fitting mask to the patient face. However, people have different facial shapes, and these off-the-shelf masks sometimes leak air or are uncomfortable. This research will assess whether personalised face masks are better than off-the-shelf masks.

Who can participate?

Adults with sleep-disordered breathing with an apnoea hypopnea index (AHI) of more than 15 events/hour who need PAP therapy and adult patients who have never had PAP therapy.

What does the study involve?

People who are under the care of the Royal Free London NHS Foundation Trust's sleep and ventilation service and who need treatment for their sleep-disordered breathing with PAP therapy will be asked to test the customised masks. The research will look at how the customised masks compare to commercially available "off the shelf" masks. It will measure how the two masks affect how well the breathing machines treat breathing problems during sleep. Further tests will see if there is a difference in the following:

- 1. How well the mask fits
- 2. How much do patients use their breathing machine
- 3. How often do people get skin sores
- 4. People's wellbeing
- 5. Feedback on the comfort of the masks.

This is a randomised controlled trial, which means there will be two groups of patients. One group will be issued with an off-the-shelf mask and one group will be issued with a customised mask. A computer will randomly decide which group each patient will be in. Neither the participant, the research team nor anyone else involved in patient care can decide. If participants

decide to take part, each will be asked to complete a consent form and if partaking will be informed when the appointments are. Appointments will be made on a day and time that is convenient for everyone who wants to take part. Before being invited to test the masks, the masks will be tested on small scale in 10 healthy people and 10 people with sleep-disordered breathing. Taking part in this study will involve attending three to four sessions with a member of the research team.

The information below shows what is involved at each visit.

Visit number 1

Off-the-shelf mask group:

We will complete a physical assessment of you

You will be given your PAP machine (CPAP, NIV) and an off-the-shelf mask

We will ask you to complete some questionnaires

A scan of your face will be collected using a handheld scanner

Customised mask group:

A scan of your face will be collected using a handheld scanner

We will complete a physical assessment of you

We will ask you to complete some questionnaires

Visit number 2, 3 months after your first visit

Off-the-shelf mask group:

We will ask you to complete some questionnaires

We will ask you to complete a two-night sleep study

We will complete a physical assessment of you

We will download some information from your PAP machine

Customised mask group:

As soon as possible after your first visit

You will be given your PAP therapy device (CPAP, NIV) and customised mask

Visit number 3, 6 months after your first visit

Off-the-shelf mask group:

We will ask you to complete some questionnaires

We will ask you to complete a two-night sleep study

We will complete a physical assessment of you

We will download some information from your PAP machine

Customised mask group:

3 months after your first visit

We will ask you to complete some questionnaires

We will ask you to complete a two-night sleep study

We will complete a physical assessment of you

We will download some information from your PAP machine

Visit number 4, 6 months after your first visit

There are no actions for the off-the-shelf mask group

Customised mask group:

We will ask you to complete some questionnaires

We will ask you to complete a two-night sleep study

We will complete a physical assessment of you

We will download some information from your PAP machine

We will issue you with an off-the-shelf mask for ongoing treatment

The visit when patients are issued with a PAP machine (visit 1 or 2) will last a maximum of 2 hours. Visits after that will last a maximum of an hour and a half. It may be possible for some of these visits to be conducted via a video platform. If support is required in between the visits, patients will be able to contact the team via phone and email. Patients will be in the study for 6 months in total. The customised mask will have to be returned at the last appointment because the customised masks have not gone through the necessary government and regulatory approvals for long-term use.

What are the possible benefits and risks of participating?

By participating in the study patients will have additional monitoring and extra tests to check their condition. It is hoped that this new way of creating masks will help people to find it easier to wear their masks. It might reduce the side effects people experience from the mask. There is a possibility in the long term that it could reduce costs and waste to the healthcare system. Taking part in the study will take up some time. There is a small risk that people could develop a skin reaction to the materials used in both the off-the-shelf masks and the customised mask. The off-the-shelf masks are made from silicon with a low reported incidence of skin reactions. The customised masks will contain silicon, with a low reported incidence of skin reactions in other products. The customised masks will be based on polyacrylate and be cured to avoid irritation.

Where is the study run from?
Royal Free London NHS Foundation Trust (UK) and University College London (UK)

When is the study starting and how long is it expected to run for? July 2021 to May 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR) Academy (UK); Grant Codes: NIHR302337

Who is the main contact? Stephanie Mansell, Stephanie.mansell.21@ucl.ac.uk (UK)

Study website

http://www.3DPiPPIn.co.uk

Contact information

Type(s)

Scientific

Contact name

Ms Francesca Gowing

Contact details

Clinical Trial co-ordinator (Therapies)
Royal Free London NHS Foundation Trust
Royal Free Hospital
Physiotherapy Department Rheumatology Research Office
Lower Ground Floor Pond Street
London
United Kingdom
NW3 2QG

+44 (0)207 317 7544 francesca.gowing@nhs.net

Type(s)

Principal Investigator

Contact name

Ms Stephanie Mansell

ORCID ID

http://orcid.org/0000-0002-2806-380X

Contact details

Royal Free Hopsital Pond Street London United Kingdom NW3 2QG +44 (0)2074726623 stephanie.mansell.21@ucl.ac.uk

Type(s)

Scientific

Contact name

Prof Silvia Schievano

ORCID ID

http://orcid.org/0000-0003-2037-5339

Contact details

University College London
Level 8
Nurses Home
Cardiac Unit
Great Ormond Street Hospital for Children
Great Ormond Street
London
United Kingdom
WCIN 3JH
+44 (0)2076792000
s.schievano@ucl.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

275073

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 54299, IRAS 275073

Study information

Scientific Title

The clinical impact of customised positive airway pressure (PAP) therapy interfaces versus usual care in the treatment of patients with sleep-disordered breathing

Acronym

3DPiPPIn 2

Study objectives

Customised interfaces will result in greater improvements in residual apnoea hypopnea index (AHI) compared to conventional interfaces

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 02/12/2022, South Central – Hampshire B (Meeting held by video-conference via Zoom; +44 (0)207 104 8088, (0)20 7104 8289, (0)20 7104 8289; hampshireb.rec@hra.nhs.uk), ref: 22/SC/0405

Study design

Randomized controlled trial

Primary study design

Interventional

Secondary study design

Nested qualitative study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Respiratory disorders

Interventions

The following examinations and investigations (if not already performed as part of routine standard of care) shall be performed for determining eligibility for enrolment into this Investigation:

RCT

A 3D scan using a hand-held scanner of all participants' faces will be collected.

Participants will undergo a physical assessment to collect sociodemographic and anthropometric data and measure the prevalence of pressure ulcers via the European Pressure Ulcer Advisory Panel (EPUAP) score. This will be conducted at baseline, 3 months and 6 months.

Participants will complete the following questionnaires at baseline, 3 months and 6 months: Epworth Sleepiness Scale (ESS), Sleepiness-Wakefulness Inability and Fatigue test (SWIFT), S3-non-invasive ventilation (S3NIV) and interface questionnaire.

Participants will undergo an initial 10-minute trial of PAP therapy with the customised 3D-printed mask to assess for mask leaks, skin reactions and comfort scores. If there are no serious adverse events/reactions during the PAP trial with the 3-D printed mask, patients will go on to have PAP therapy as per their normal PAP regime.

Participants will undergo a two-night cardiorespiratory sleep study at baseline, 3 months and 6 months.

Participants on NIV will have a capillary blood gas (CBG) at baseline, 3 and 6 months

Data from participants' PAP therapy devices will be downloaded at 3 months and 6 months, Specific data collected will be:

Compliance with PAP therapy, measured as hours and percentage of days PAP therapy used >4 hours/night over 28 days, measured prior to 3 months and 6 months in concordance with internationally recognised definitions of compliance.

Interface leak, measured as average L/min and percentage of the intentional leak over 7 days

Nested Qualitative study

Participants recruited for the nested qualitative study will undergo a 1:1 semi-structured interview at a location of the patients choosing.

Following their participation in the trial patients will receive ongoing care from the sleep and ventilation team as per standard care.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

3D printing positive pressure interfaces

Primary outcome measure

Apnoea hypopnea index (AHI) measured using the limited cardio-respiratory sleep study at 6 months

Secondary outcome measures

- 1. Apnoea hypopnea index (AHI) measured using the limited cardio-respiratory sleep study at 3 months
- 2. Interface leak measured using average L/min and percentage of the intentional leak over 7 days from positive airway pressure (PAP) therapy data downloads at 3 and 6 months
- 3. Residual AHI measured using PAP therapy data downloads for further validation of AHI at 3 and 6 months
- 4. Incidence of pressure ulcers measured using the European Pressure Ulcer Advisory Panel (EPUAP) score (0 to 4) at 3 and 6 months
- 5. Compliance with PAP therapy, measured as hours and percentage of days PAP therapy used >4 hours/night over 28 days, measured prior to 3 and 6 months
- 7. Symptoms measured using the Epworth Sleepiness Score (ESS) and Sleepiness-Wakefulness Inability and Fatigue test (SWIFT) at baseline, and 3 and 6 months.
- 8. Comfort as measured by the S3-non-invasive ventilation (S3NIV) questionnaire and the interface questionnaire, at baseline, and 3 and 6 months.

Overall study start date

01/07/2021

Completion date

31/05/2026

Eligibility

Key inclusion criteria

Randomised controlled trial:

- 1. Diagnosis of SDB (AHI > = 15) confirmed with a home-based sleep study and requiring PAP therapy
- 2. Patients naive to domiciliary PAP therapy
- 3. Age > = 18years

Nested Qualitative study:

Patients participating in study 1

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 160; UK Sample Size: 160

Key exclusion criteria

Randomised controlled trial:

- 1. AHI < 15
- 2. Excessive facial hair which they are unwilling to shave
- 3. Age < 18 years
- 4. Existing facial pressure ulcers
- 5. Unable to provide informed consent
- 6. Known allergy to silicone
- 7. Keloid scarring
- 8. Previous domiciliary PAP therapy

Nested Qualitative study Patients who are unable to provide informed consent

Date of first enrolment

16/01/2023

Date of final enrolment

31/05/2024

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Royal Free Hospital

Pond Street London United Kingdom NW3 2QG

Sponsor information

Organisation

University College London

Sponsor details

C/o: Pushpsen Joshi 4th Floor West 250 Euston Road London England United Kingdom NW1 2PG +44 (0)20 3447 9928 uclh.randd@nhs.net

Sponsor type

Hospital/treatment centre

Website

http://www.ucl.ac.uk/

ROR

https://ror.org/02jx3x895

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

31/05/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to maintaining the anonymity of patients as the study team is unable to anonymise the date

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
HRA research summary			28/06 /2023	No	No
Protocol article		14/11 /2024	15/11 /2024	Yes	No
Other publication	Lived experiences of patients using positive airway pressure (PAP) therapy: a nested phenomenological study within the 3DPiPPIn randomised controlled trial	06/05 /2025	08/05 /2025	Yes	No